American Research & Management Co. lifted its position in iShares NASDAQ Biotechnology Index (NASDAQ:IBB) by 183.4% during the fourth quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 2,820 shares of the financial services provider’s stock after buying an additional 1,825 shares during the period. American Research & Management Co.’s holdings in iShares NASDAQ Biotechnology Index were worth $301,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. FNY Partners Fund LP acquired a new stake in shares of iShares NASDAQ Biotechnology Index during the third quarter worth $133,000. Wharton Business Group LLC acquired a new stake in shares of iShares NASDAQ Biotechnology Index during the third quarter worth $208,000. New England Investment & Retirement Group Inc. acquired a new stake in shares of iShares NASDAQ Biotechnology Index during the third quarter worth $213,000. Leavell Investment Management Inc. acquired a new stake in shares of iShares NASDAQ Biotechnology Index during the third quarter worth $214,000. Finally, Fishman Jay A Ltd. MI acquired a new stake in shares of iShares NASDAQ Biotechnology Index during the third quarter worth $247,000. 27.28% of the stock is currently owned by institutional investors.

Shares of iShares NASDAQ Biotechnology Index (IBB) opened at $107.54 on Wednesday. The stock has a market capitalization of $9,460.00, a price-to-earnings ratio of 3.55 and a beta of 1.37. iShares NASDAQ Biotechnology Index has a 52-week low of $94.20 and a 52-week high of $119.30.

COPYRIGHT VIOLATION NOTICE: This piece was originally published by TheOlympiaReport and is the sole property of of TheOlympiaReport. If you are accessing this piece on another site, it was illegally copied and reposted in violation of U.S. & international trademark and copyright legislation. The correct version of this piece can be viewed at https://theolympiareport.com/2018/02/14/american-research-management-co-boosts-stake-in-ishares-nasdaq-biotechnology-index-ibb.html.

iShares NASDAQ Biotechnology Index Profile

iShares Nasdaq Biotechnology ETF (the Fund), formerly iShares Nasdaq Biotechnology Index Fund, is an exchange-traded fund (ETF). The Fund seeks investment results that correspond generally to the price and yield performance of the NASDAQ Biotechnology Index (the Index). The Index contains securities of NASDAQ listed companies that are classified according to the Industry Classification Benchmark as either biotechnology or pharmaceuticals, which also meet other eligibility criteria determined by NASDAQ.

Want to see what other hedge funds are holding IBB? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for iShares NASDAQ Biotechnology Index (NASDAQ:IBB).

Institutional Ownership by Quarter for iShares NASDAQ Biotechnology Index (NASDAQ:IBB)

Receive News & Ratings for iShares NASDAQ Biotechnology Index Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for iShares NASDAQ Biotechnology Index and related companies with MarketBeat.com's FREE daily email newsletter.